[1] Wong R,Frenette C. Updates in the management of hepatocellular carcinoma[J]. Gastroenterol Hepatol(N Y),2011,7(1):16-24. [2] Zhang S,Li J,Liu PG,et al.Pygopus-2 promotes invasion and metastasis of hepatic carcinoma cell by decreasing E-cadherin expression[J].Oncotarget, 2015,6(13):11074-11086. [3] Chen X,Song B,Lin Y,et al.PTK6 promotes hepatocellular carcinoma cell proliferation and invasion[J].Am J Transl Res,2016,8(10):4354-4361. [4] 甘声通,胡向阳,陈若冰,等.肝细胞生长因子/c-Met信号通路在肝癌恶性行为中的作用[J].生命的化学,2017,37(3):349-354. [5] Mitra S,Ghosh B,Gayen N,et al.Bipartite role of heat shock protein 90(Hsp90) keeps CRAF kinase poised for activation[J].J Biol Chem,2016,291(47):24579-24593. [6] Atefi M,Titz B,Tsoi J,et al.CRAF R391W is a melanoma driver oncogene[J].Sci Rep,2016,6:27454. [7] Cepeda MA,Evered CL,Pelling JJH,et al.Inhibition of MT1-MMP proteolytic function and ERK1/2 signalling influences cell migration and invasion through changes in MMP-2 and MMP-9 levels[J].J Cell Commun Signal,2017,11(2):167-179. [8] Chen L,Li M,Li Q,et al.DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway[J].Mol Cancer,2013,12:157. [9] Yu Y,Song J,Zhang R,et al.Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma[J].Oncotarget,2017,8(45):79722-79730. [10] 李雅睿,王梦瑶,卢桂芳,等.DNMT3B基因在肝细胞癌中的表达及其对肝癌细胞增殖和侵袭迁移的影响[J].西安交通大学学报:医学版,2017,38(3):380-385. [11] Chatelle CV,Hövermann D,Müller A,et al.Optogenetically controlled RAF tocharacterize BRAF and CRAF protein kinase inhibitors[J].Sci Rep,2016,6(3):23713. [12] Kamata T,Hussain J,Giblett S,et al.BRAF inactivation drives aneuploidy by deregulating CRAF[J].Cancer Res,2010,70(21):8475-8486. [13] Montagut C,Sharma SV,Shioda T,et al.Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma[J].Cancer Res,2008,68(12):4853-4861. [14] Mielgo A,Seguin L,Huang M,et al.A MEK-independent role for CRAF in mitosis and tumor progression[J].Nat Med,2011,17(12):1641-1645. [15] Sun X,Li J,Sun Y,et al.miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways[J].Oncotarget,2016,7(33):53558-53570. [16] Lochhead PA,Clark J,Wang LZ,et al.Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation[J].Cell Cycle,2016,15(4):506-518. [17] Kuliczkowski W,Radomski M,Gąsior M,et al.MMP-2,MMP-9,and TIMP-4 and response to aspirin in diabetic and nondiabetic patients with stable coronary artery disease:A pilot study[J].Biomed Res Int,2017,2017:9352015. [18] Webb AH,Gao BT,Goldsmith ZK,et al.Inhibition of MMP-2 and MMP-9 decreases cellular migration,and angiogenesis in vitro models of retinoblastoma[J].BMC Cancer,2017,17(1):434. [19] Shi WZ,Ju JY,Xiao HJ,et al.Dynamics of MMP-9, MMP-2 and TIMP-1 in a rat model of brain injury combined with traumatic heterotopic ossification[J].Mol Med Rep,2017,15(4):2129-2135. [20] Zhang QY,Li R,Zeng GF,et al.Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression[J].World J Gastroenterol,2014,20(29):10082-10093. [21] Roomi MW,Kalinovsky T,Rath M,et al.In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines,inducers and inhibitors[J].Int J Oncol,2014,44(1):27-34. |